Evidence map›Paper›PMID 40548400›Full record

ArticleInternational journal of cancer2025

Prediagnostic plasma metabolite concentrations and liver cancer risk: A nested case-control study with long follow-up in the Shanghai Women's Health Study.

Qiu-Ming Shen, Zhuo-Ying Li, Jing Wang, Yi-Xin Zou, Jie Fang, Li-Feng Gao, Yu-Ting Tan, Hong-Lan Li, Yong-Bing Xiang

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qiu-Ming ShenState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-5144-8102
Zhuo-Ying LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing WangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yi-Xin ZouState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie FangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li-Feng GaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu-Ting TanState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hong-Lan LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yong-Bing XiangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-3840-9915

Funding

Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
National Key Research and Development Program of China 2021YFC2500404National Key Research and Development Program of China 2021YFC2500405NCI NIH HHS UM1 CA182910Shanghai Cancer Institute SB23-20
6 · The paper itself

Abstract

Present knowledge on metabolic perturbation prior to liver cancer is limited, with most studies unable to quantify the absolute concentrations of metabolites and lacking a focus on female-specific findings. We conducted a 1:1 matched nested case-control study (187 pairs of cases and controls) within the Shanghai Women's Health Study. A targeted metabolomics method was used to quantify 186 metabolites in plasma samples collected at recruitment. A multivariable conditional logistic regression model was utilized to estimate the odds ratio (OR) and 95% confidence interval (CI). Restricted cubic spline function was used to characterize the dose-response associations. A pathway analysis was conducted to identify the most relevant pathways. A metabolic score was calculated via a linear combination of metabolites with nonzero coefficients in the LASSO logistic regression model. After adjustment for potential confounders and correction for multiple testing, 27 metabolites were associated with liver cancer risk and a non-linear association was observed for glutamic acid. Primary bile acid biosynthesis and amino acid biosynthesis and metabolism were important pathways involved in the etiology. A metabolic score derived from 10 metabolites showed a positive linear association with liver cancer risk (OR

Indexed as

Biomarkers, TumorLiver NeoplasmsAdultAgedCase-Control StudiesChinaFemaleFollow-Up StudiesHumansMetabolomicsMiddle AgedRisk FactorsWomen's HealthBiomarkers, Tumorliver cancermetabolomicspathway analysisprospective studyrisk prediction

Identifiers

PMID40548400
PMCPMC12246391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.